Kineta announced new data showing that KIN 1148 enhanced the efficacy of existing flu vaccines in animal models through a balanced immune response. Moreover, this enhanced effect was accomplished while using lower vaccine doses.
KIN 1148 is a novel vaccine adjuvant targeting IRF-3 innate immune pathways that can potentially induce a protective immune response, boost neutralizing antibodies and reduce inflammation. This compound allows for a targeted approach that stimulates innate immune protective pathways. It also offers more than 15-fold dose sparing effect which can then maximize the supply of influenza split vaccines.
KIN 1148 was discovered through the Company’s AViid discovery platform that focused on molecules which activate the IRF-3 dependent innate immune pathways. The vaccine adjuvants can also help the existing vaccines’s protection if it generates a stronger initial response. The adjuvant has shown efficacy in in vivo models of highly pathogenic avian influenza and West Nile virus infection.
For more information call (206) 378-0400 or visit Kinetabio.com.